Myriad Genetics (MYGN) UBS Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
UBS Global Healthcare Conference summary
10 Nov, 2026Q2 pressures and guidance
Q2 revenue fell 11% and ASP fell 9%; prenatal volume and average revenue per test remained soft, while hereditary cancer reimbursement pressure also weighed on results.
Updated guidance assumes Q2-suppressed ASP persists through H2, no improvement in prenatal volume, and no benefit from new products or added sales capacity.
H1 revenue multiplied by two is a couple million dollars above the updated guidance midpoint; historically, H2 contributes about 52% of annual revenue.
Guidance assumes new salespeople remain at Q2 efficiency levels; productivity typically takes quarters to build.
Reimbursement and operational initiatives
Revenue Cycle Management Optimization is targeting execution across people, processes and tools to reduce billing friction and improve collections; progress was reported over the preceding months.
Hereditary cancer pressure from several payers was not attributed to medical-policy changes; a separate, medium- to long-term effort aims to align payer policy, guidelines and clinical practice.
Project Ascend is a multiyear effort spanning commercial operations, revenue cycle and other processes, targeting cost savings, revenue synergies and scalability; initial benefits are expected in 2027, with actions continuing into 2028.
Portfolio decisions intended to materially strengthen revenue, profitability, gross margin and liquidity were expected to be shared within the next couple of months.
Investment and portfolio choices are increasingly centered on the Cancer Care Continuum, with decisions assessing patient and provider value, customer relationships, competitive capabilities and profitability.
Hereditary cancer and prenatal testing
MyRisk volume growth had continued for several quarters; management cited potential to sustain high-single-digit to low-double-digit growth and a $7B market, including ~$5B in unaffected patients with less than one-third penetration.
Growth drivers include an updated polygenic risk score, a dedicated unaffected-market sales team established April 1, market-activation campaigns and 2026 guideline additions for ovarian, colorectal and gastric cancers.
Prenatal performance was below expectations amid intensified competition and sales-force changes; stabilization signals include a smaller quarterly decline, new-customer volume offsetting losses, then overall volume stability and growth.
FirstGene launched about a month before the conference, combining maternal and fetal screening from one blood draw as early as eight weeks, with results within 14 days; returning customers and positive early feedback were noted.
FirstGene uses existing billing codes; average revenue per test exceeds the legacy prenatal portfolio with consistent COGS, making tests accretive to gross margin and profitability.
Latest events from Myriad Genetics
- Prenatal divestiture and Ascend reset the 2027 growth and profitability agenda.MYGN
2026 Stephens Annual Investment Conference | NASH2026 - Higher guidance and a planned $210M Prenatal Health sale follow sequential Q3 gains.MYGN
Q3 2026 - Revenue and ASPs declined, but strategic focus on cancer care and operational initiatives aim to drive recovery.MYGN
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue dropped 11% year-over-year, leading to lower guidance and efficiency actions.MYGN
Q2 2026 - All proposals passed, directors elected, and no stockholder questions were raised.MYGN
AGM 2026 - Q1 2026 revenue rose 2% to $200.4M, with strong cancer and mental health growth; guidance reaffirmed.MYGN
Q1 2026 - Q3 2024 revenue up 11%, but GeneSight faces major payor risk in 2025.MYGN
Q3 2024 - Q1 2025 revenue fell 3% year-over-year; 2025 guidance lowered amid GeneSight and hereditary cancer headwinds.MYGN
Q1 2025 - 2024 revenue up 11% to $838M, with strong segment growth and reaffirmed 2025 guidance.MYGN
Q4 2024